TargetBeta
CD8A
CD8 subunit alpha · also p32, CD8alpha, CD8 · CD molecules
6 programs in company-led studies act on CD8A, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| zamtocabtagene autoleucelrule | Miltenyi Biomedicine | phase 2 | 87 running | CD19, CD4, MS4A1 | NCIt |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 22 running | CD3E, MS4A1 | a judged reading |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 11 running | CD3E, GPC3 | a judged reading |
| Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621 | AstraZeneca | phase 2 | 11 running | CD3E, STEAP2 | a judged reading |
| CD8-guided IL-2 Fusion Protein AZD6750 | AstraZeneca | phase 2 | 11 running | IL2RB, IL2RG | a judged reading |
| etakafusp alfarule | Amgen | phase 1 | 22 running | – | NCIt |
Conditions their studies are in
- Melanoma, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Lupus Erythematosus, Systemic, 1 program
- Lupus Nephritis, 1 program
- Lymphoma, B-Cell, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Multiple Sclerosis, 1 program
- Prostatic Neoplasms, 1 program
- Small Cell Lung Carcinoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026zamtocabtagene autoleucel · Miltenyi Biomedicine · phase 2 · NCT04792489
- May 5, 2027Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 · AstraZeneca · phase 2 · NCT06916806
- Jun 30, 2027Anti-GPC3 T Cell-engaging Antibody AZD9793 · AstraZeneca · phase 2 · NCT06795022
- Mar 18, 2028etakafusp alfa · Amgen · phase 1 · NCT07037758
- Mar 29, 2029Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621 · AstraZeneca · phase 2 · NCT07192614
- Oct 2, 2029CD8-guided IL-2 Fusion Protein AZD6750 · AstraZeneca · phase 2 · NCT07115043
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.